Terns Pharmaceuticals, Inc. TERN · Stock Open Terns Pharmaceuticals, Inc. in new tab
Terns Pharmaceuticals, Inc. Analysis (TERN)
Is Terns Pharmaceuticals, Inc. a good investment? Terns Pharmaceuticals, Inc. (TERN) is currently trading at 52.95 USD.
Earnings Schedule: Terns Pharmaceuticals, Inc. is expected to release its next earnings report on May 14, 2026. The market consensus estimate for Forward EPS is -1.56.
Investor FAQ
Does Terns Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Terns Pharmaceuticals, Inc.?
Terns Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be May 14, 2026. The company currently has a trailing EPS of -1.03.
Company Profile
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Community Discussion